Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine sublingual formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's disease; BMND06 is in Phase I clinical trial for treatment of morbid obesity; and BMDO9 is in Phase I clinical trial for treatment of Parkinson's disease. It is also developing preclinical drug candidates, including BMND02 for the treatment of fibromyalgia; BMND03 for the treatment of addictive disorders; BMND05 to treat chronic pain; and BMND07 for the treatment of major depressive disorder. The company is headquartered in Vancouver, Canada.
Frequently asked questions
What sector does Biomind Labs Inc. (BMNDF) operate in?
Biomind Labs Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Biomind Labs Inc. (BMNDF) current stock price?
As of the latest data, Biomind Labs Inc. stock price is $0.25, with a previous close of $0.25.
What is Biomind Labs Inc. (BMNDF) current market capitalization?
Biomind Labs Inc. market cap is approximately 19.41 million.
What is Biomind Labs Inc. (BMNDF) Earnings Per Share (EPS)?
The trailing EPS is -$0.02.
What is Biomind Labs Inc. (BMNDF) EBITDA?
Biomind Labs Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -655.81 thousand.
Does Biomind Labs Inc. (BMNDF) pay dividends?
No. Biomind Labs Inc. does not pay a dividend.
What is Biomind Labs Inc. (BMNDF) beta (volatility) score?
Biomind Labs Inc. has a beta of 7.220, indicating very high volatility compared to the market.
